CLINICAL_TRIALS
trial_result
· 2022-02-11
Clinical Trial Update: Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma [Phase 2]
Summary
A Phase 2 neoadjuvant study evaluating vismodegib in patients with large and/or recurrent resectable basal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SRH Wald-Klinikum Gera GmbH | Conditions: Basal Cell Carcinoma | Phase 2 | Status: COMPLETED